Targeting of IL‐17A derived from Th17 cells is beneficial in experimental lung cancer by inhibiting lung tumor‐infiltrating T regulatory cells and inducing IFN‐γ‐producing CD4+ T cells in the presence of T‐bet (Reppert et al., 2011). The gene discussed is IFNG; the disease is lung cancer.